3rd Real-World Evidence World Congress 2025 Europe
The significance of Real-World Evidence in changing the future of trial design, drug development and healthcare to improve patient outcomes
Copthorne Tara Hotel London Kensington, London, UK
Tuesday 29th - Wednesday 30th April 2025
KEY INDUSTRY EXPERT SPEAKERS

Riad Dirani
VP, Global HEOR, Medical Operations & Excellence
Riad Dirani, PhD, is currently the VP of Global Health Economic and Outcomes Research and Medical Operations & Excellence at Teva Pharmaceuticals. His responsibilities include overseeing the HEOR, Epidemiology, RWE, Medical Operations, and Medical Communications within Medical Affairs/R&D, and developing and expanding their strategic capabilities optimize the development and commercialization of Teva’s portfolio of products and offerings globally in innovative, generic, and biosimilar medicines.
Riad has worked in the pharmaceutical industry since 2000, including positions of increasing responsibility at Aventis, GlaxoSmithKline, Pfizer, and Johnson & Johnson in multiple therapeutic areas. Riad joined Teva in 2014 to build the HEOR group and establish its operating model.
Riad received his Ph.D. in Health Services Research/Health Economics from The Pennsylvania State University.

ESTHER NZENZA
Founder and CEO
Esther Nzenza is a seasoned pharmaceutical executive with over 24 years of experience across domestic, regional and international leadership roles. Esther has built and led teams supporting all Commercial Capabilities at an International level, in both Speciality and Rare disease. As the Founder and CEO of Decisive Consulting, Esther specialises in providing the capacity and capability to enable and empower companies at “decisive moments” of their evolution, with a particular focus on Market Access, Capability Development and Commercial Strategy. Blending technical understanding, lived experience and a global network of trusted advisers, Esther and her team can accelerate and focus plans for International commercialisation.

RYOTARO ISHIKAWA
Global Market Access Director
Ryotaro joined Novartis in 2006 as Brand Manager for Transplantation & Infectious disease in Latin America and rapidly went on to hold several positions of increasing responsibility within the CPO, notably as Specialty Franchise Head and Market Access Head. He then became Regional Pricing & Access Director for the LACan Region, and subsequently moved to Basel to work as Global Market Access Director, Respiratory, currently is the Gene Therapies Head of Access for central European cluster in Novartis. Before joining Novartis, Ryotaro practiced medicine, worked as a payor, to later move into sales in medical devices and renal therapy services. Moreover, he also served in the military with the Multinational Force and Observers - UN, an international peacekeeping force based in the Sinai peninsula. He is an MD, holds both a degree in Hospital Administration and a Master in Business Administration from Universidad de los Andes in Colombia, as well as a postgraduate diploma in Intellectual Property. He has an extensive and unique experience in Commercial, Access, healthcare systems and payor environments,

JOSIE GODFREY
Co-Founder and CEO, Realise Advocacy, Director
Josie is the Director of JG Zebra Consulting which provides independent consultancy services with a focus on rare diseases and innovative technologies. She is Co-founder and CEO of Realise Advocacy which supports patient advocacy groups to maximise their impact in HTA and access. Her current projects include providing strategic market access, policy and stakeholder engagement advice, and support to pharmaceutical companies, trade bodies, and patient advocacy groups. She is the Strategic Director for Duchenne UK’s Project HERCULES, an award-winning international multi-stakeholder collaboration developing evidence and tools to support Health Technology Assessments (HTAs) for new treatments for Duchenne Muscular Dystrophy. Josie has extensive experience in rare diseases and led the establishment of the Highly Specialised Technologies programme at NICE, the National Institute for Health and Care Excellence in the UK which carries out Health Technology Assessments of treatments for very rare diseases.

Prof. Dr. Thomas Wilke, PhD
Scientific Lead
Thomas has 25 years of experience in leading and conducting German and international real-world evidence studies. Thomas holds a PhD in Economics from the University of Duisburg, Germany, and a Diploma degree in Economics from the University of Duisburg. From 2001-2004 Thomas worked for the Boston Consulting Group. He worked as scientific head of the Global RWE teams of Ingress-health (2015-2019) and Cytel (2019-
2023).
Since 2004 Thomas is a Professor at the Faculty of Business at the University of Applied Sciences Wismar, Germany. He acts as head of various institutions in the German healthcare system that have responsibility for physician and hospital planning (Landesausschuss / Erweiterter Landesausschuss). Thomas is also leading a German University-affiliated research institute (IPAM). Finally, he works as Senior Scientific Lead for GIPAM, a Global Health Care Consultancy.
In the recent year, Thomas primarily worked on various RWE studies as well as the development of innovative solutions for Evidence Generation Planning (EVIGATOR) and AI-based evidence synthesis (ANCHOR).

Marc De Benedetti, Ph.D.
Global Biometrics & Data Sciences, MMA, RWE CoE, BMS
Marc is biostatistician at Bristol Myers Squibb, specializing in working with real-world data and the use of real-world evidence in regulatory decision making, and the use of propensity score methods in externally controlled single-arm trials.